{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.5","upperLimit":"9.5","value":"8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"}],"units":"Participants"}],"description":"Measure from date of registration to date of death due to any cause. Patients last known to be alive are censored at date of last contact.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive MLN8237 (alisertib) PO BID on days 1-7. Treatment repeats every 21 days for 17 courses in the absence of disease progression or unacceptable toxicity","id":"OG000","title":"MLN8237"}],"paramType":"MEDIAN","populationDescription":"Only eligible patients were included in the analysis.","reportingStatus":"POSTED","timeFrame":"Up to 2 years after registration","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}